Lv61
2440 积分 2024-10-11 加入
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
8小时前
已完结
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
8小时前
已完结
Management of Advanced Hepatocellular Carcinoma: A Review and Practical Guide
8小时前
求助中
Neoadjuvant therapy for pancreatic cancer
1个月前
已完结
Cathepsin K is Superior to HMB45 for the Diagnosis of Pulmonary Lymphangioleiomyomatosis
2个月前
已完结
Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions
3个月前
已完结
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint inhibitors for the Treatment of Biliary Tract Cancer
3个月前
已完结
Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma
3个月前
已完结
Comparison of different criteria for estimating major pathological response in resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy
4个月前
已完结
Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension
4个月前
已完结
皖公网安备34019202002308
